International Journal of Cancer Management

Published by: Kowsar

HER-2/neu Overxpression in Esophageal Squamous Cell Carcinoma (ESCC) and Its Correlation with Patient’s Clinicopathological Features

Ali Taghizadeh Kermani 1 , Rosita Vakili 2 , Samaneh Dadkhah 3 , Amir Hossein Jafarian 4 and Reza Bagheri 5 , *
Authors Information
1 Cardiothoracic Surgery and Transplant Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Center of Pathological and Medical Diagnostic Services, Iranian Academic Center for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, IR Iran
3 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
4 Cancer Molecular Pathology Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Cardio-Thoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: October 2016, 9 (5); e5007
  • Published Online: September 28, 2016
  • Article Type: Research Article
  • Received: December 9, 2015
  • Accepted: September 24, 2016
  • DOI: 10.17795/ijcp-5007

To Cite: Taghizadeh Kermani A, Vakili R, Dadkhah S, Jafarian A H, Bagheri R. HER-2/neu Overxpression in Esophageal Squamous Cell Carcinoma (ESCC) and Its Correlation with Patient’s Clinicopathological Features, Int J Cancer Manag. 2016 ; 9(5):e5007. doi: 10.17795/ijcp-5007.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Yomralioglu T, Colak EH, Aydinoglu AC. Geo-relationship between cancer cases and the environment by GIS: a case study of Trabzon in Turkey. Int J Environ Res Public Health. 2009; 6(12): 3190-204[DOI][PubMed]
  • 2. Pourfarzi F. The Features of Esophageal Cancer in Ardabil Province: Report of a Population-based Cancer Registry in Northwest Iran. Govaresh. 2011; 16(1): 55-60
  • 3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97(2): 142-6[DOI][PubMed]
  • 4. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009; 9: 6[DOI][PubMed]
  • 5. Han X, Diao L, Xu Y, Xue W, Ouyang T, Li J, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014; 25(6): 1158-64[DOI][PubMed]
  • 6. Raziei H. HER-2/neu Expression in Resectable Gastric Cancer and its Relationship with Histopathologic Subtype, Grade, and Stage. Iran J Basic Med Sci. 2007;
  • 7. Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst. 2005; 97(12): 870-1[DOI][PubMed]
  • 8. Wang G, Zhang W, Jiang W, Luan L. Overexpression of her-2 associated with the progression of esophageal cancer patients. Hepatogastroenterology. 2013; 60(128): 1972-8[PubMed]
  • 9. Won E, Janjigian YJ, Ilson DH. HER2 directed therapy for gastric/esophageal cancers. Curr Treat Options Oncol. 2014; 15(3): 395-404[DOI][PubMed]
  • 10. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 2007; 20(2): 192-8[DOI][PubMed]
  • 11. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007; 20(1): 120-9[DOI][PubMed]
  • 12. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park). 2002; 16(10): 1340-8[PubMed]
  • 13. Alimoghaddam K, Jalali A, Aliabadi LS, Ghaffari F, Maheri R, Eini E, et al. The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience. Int J Hematol Oncol Stem Cell Res. 2014; 8(2): 9-13[PubMed]
  • 14. Khan AP, Contessa JN, Nyati MK, Ross BD, Rehemtulla A. Molecular imaging of epidermal growth factor receptor kinase activity. Anal Biochem. 2011; 417(1): 57-64[DOI][PubMed]
  • 15. Dahlberg PS, Ferrin LF, Grindle SM, Nelson CM, Hoang CD, Jacobson B. Gene expression profiles in esophageal adenocarcinoma. Ann Thorac Surg. 2004; 77(3): 1008-15[DOI][PubMed]
  • 16. Lim SC. Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma. Biomed Pharmacother. 2005; 59 Suppl 2: 366-9[PubMed]
  • 17. Pedram A, Mahmodlou R, Enshayi A, Sepehrvand N. Esophageal cancer in northwestern Iran. Indian J Cancer. 2011; 48(2): 165-9[DOI][PubMed]
  • 18. Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, de Reis BS, Quintella DC, et al. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer. 2012; 12: 569[DOI][PubMed]
  • 19. Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013; 42(4): 1151-8[DOI][PubMed]
  • 20. Huang JX. HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Letters. 2013; 6: 13-8[DOI]
  • 21. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006; 19(4): 224-31[DOI][PubMed]
  • 22. Angiero F, Sordo RD, Dessy E, Rossi E, Berenzi A, Stefani M, et al. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? J Oral Pathol Med. 2008; 37(3): 145-50[DOI][PubMed]
  • 23. Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009; 22(6): 496-504[DOI][PubMed]
  • 24. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007; 31(3): 493-9[PubMed]
  • 25. Wu D, Xu J, Yu G, Zhang B, Wang H, Wang C, et al. Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepatogastroenterology. 2013; 60(121): 99-106[DOI][PubMed]
  • 26. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012; 18(2): 546-54[DOI][PubMed]
  • 27. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005; 92(7): 1253-60[DOI][PubMed]
  • 28. Jeung J, Patel R, Vila L, Wakefield D, Liu C. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. Arch Pathol Lab Med. 2012; 136(6): 610-7[DOI][PubMed]
  • 29. Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, et al. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study. Breast. 2013; 22(3): 301-8[DOI][PubMed]
  • 30. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012; 29(2): 933-40[DOI][PubMed]
  • 31. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013; 8: 76[DOI][PubMed]
  • 32. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, et al. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014; 120(3): 415-24[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments